Sanders Capital LLC Lowers Stock Position in Elevance Health, Inc. $ELV

Sanders Capital LLC cut its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 1.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 5,768,918 shares of the company’s stock after selling 56,290 shares during the period. Elevance Health makes up 2.3% of Sanders Capital LLC’s portfolio, making the stock its 14th biggest position. Sanders Capital LLC’s holdings in Elevance Health were worth $1,864,053,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ELV. Physician Wealth Advisors Inc. increased its holdings in shares of Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after buying an additional 63 shares during the last quarter. Activest Wealth Management lifted its holdings in shares of Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after acquiring an additional 34 shares during the last quarter. Rossby Financial LCC grew its position in Elevance Health by 110.0% in the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after acquiring an additional 44 shares in the last quarter. Vermillion & White Wealth Management Group LLC grew its position in Elevance Health by 94.9% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after acquiring an additional 37 shares in the last quarter. Finally, Motco increased its stake in Elevance Health by 334.8% in the third quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after acquiring an additional 77 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Up 1.3%

ELV opened at $291.69 on Friday. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $458.75. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. The business’s 50-day moving average price is $338.25 and its 200-day moving average price is $334.11. The company has a market cap of $64.38 billion, a P/E ratio of 11.61, a P/E/G ratio of 1.59 and a beta of 0.51.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. During the same period in the prior year, the business posted $3.84 EPS. Elevance Health’s quarterly revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.4%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s payout ratio is currently 27.39%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ELV. Weiss Ratings downgraded Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, February 2nd. Sanford C. Bernstein reduced their price objective on Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Wolfe Research set a $425.00 price objective on Elevance Health and gave the company an “outperform” rating in a report on Thursday, January 8th. TD Cowen restated a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Finally, UBS Group set a $400.00 target price on Elevance Health in a research note on Thursday, January 29th. Twelve equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Elevance Health currently has an average rating of “Moderate Buy” and an average price target of $387.40.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.